Wave Life Sci Ord Sh (WVE) Stock Price, Quote & News

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 ant...

Industry: Biotechnology

Sector: Healthcare

Phone: 65 6236 3388

Website: wavelifesciences.com

Address:

Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore

YFZ450 Dec. 27 at 6:52 PM

$WVE half the MC of $HIMS on a phase one trial lol so whos under valued and whos over valued?? And bought and paid for analyst calling for a higher mc... scam job 101

0 · Reply

satrasal Dec. 27 at 4:45 PM

$WVE Wave raised $350M at $19 (GSK anchor) using obesity data to de-risk the AATD binary. Officers sold some as well to derisk. Short interest decreased from 16 to 14.6mil. Is WVE poised to ramp? The Tell- Wve jan calls OI held through the runup and after; it increased bigly on the offering dip. Calls bought for 50c did not cash out at $6; they added to them for 1-3 depending on the strike. The Jan "sticky" OI growth, is a bet on a Jan 12-15 JPM conf, aatd readout. If hit, the platform is validated, targeting $30. Failure crashes the stock to ~$12, shifting focus to Obesity IND (Feb/Mar) and Huntington’s multi-dose data (H1 '26). Watching for the JPM time slot next week.

0 · Reply

History101 Dec. 26 at 6:53 PM

$WVE 5d and 1mo charts look great!!

0 · Reply

History101 Dec. 25 at 3:12 AM

$WVE lovin the 5d chart

0 · Reply

kshonstocks Dec. 24 at 4:52 PM

$WVE turning back up

0 · Reply

MansNotHot123 Dec. 24 at 3:52 PM

$WVE shorting here 18.40

0 · Reply

johnnygogogo Dec. 24 at 3:32 PM

$WVE a whole 2 more points of upside to get to the place where several Board members decided they would rather have some cash than stay fully invested. Pretty sure this is being propped just so Leerink doesn’t take a bath on the secondary. And still not sure they closed it.

0 · Reply

B_B_ Dec. 24 at 3:13 PM

$TMC $WVE $ORCL Green, green, green, it's already a Merry Christmas for me!

0 · Reply

VignetteVestor Dec. 24 at 11:56 AM

$WVE Current positioning will be tested as management navigates capital constraints while advancing core initiatives. Clear inflection points are required to justify renewed interest.

0 · Reply

Mantraset3 Dec. 24 at 9:42 AM

$WVE taking profit here before year end, a lot of time still needed for more approvals / stage trials — will be interesting to get back in at under $10. Merry Christmas!

1 · Reply

Why Did Wave Life Sciences Surge 147%?

Dec 9, 2025, 9:50 PM EST - 19 days ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 9, 2025, 2:11 PM EST - 20 days ago

What's Going On With Wave Life Sciences Stock Tuesday?

Dec 8, 2025, 4:01 PM EST - 21 days ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 3:17 PM EST - 21 days ago

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Dec 8, 2025, 7:30 AM EST - 21 days ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Dec 7, 2025, 4:00 PM EST - 22 days ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Dec 5, 2025, 4:12 PM EST - 24 days ago

Wave Life Sciences: Being Realistic, There Is Still So Much To Prove

Nov 11, 2025, 11:46 AM EST - 6 weeks ago

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Nov 10, 2025, 8:01 PM EST - 7 weeks ago

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 7 weeks ago

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:30 AM EST - 7 weeks ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:30 PM EST - 7 weeks ago

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Nov 4, 2025, 8:30 AM EST - 7 weeks ago

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Nov 1, 2025, 3:06 AM EDT - 2 months ago

Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript

Oct 29, 2025, 10:50 PM EDT - 2 months ago

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 4:15 PM EDT - 2 months ago

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Sep 18, 2025, 8:30 AM EDT - 3 months ago

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Sep 3, 2025, 3:10 PM EDT - 4 months ago

Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript

Sep 3, 2025, 1:28 PM EDT - 4 months ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

GSK

Sep 3, 2025, 7:30 AM EDT - 4 months ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Jul 30, 2025, 9:38 PM EDT - 5 months ago

Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:30 AM EDT - 5 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 8:30 AM EDT - 5 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Jul 7, 2025, 5:42 PM EDT - 6 months ago

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

Jun 20, 2025, 4:01 PM EDT - 6 months ago

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

May 29, 2025, 8:30 AM EDT - 7 months ago

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 7 months ago

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 9, 2025, 4:57 PM EDT - 8 months ago

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 8 months ago

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:30 AM EDT - 8 months ago

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Mar 27, 2025, 3:54 PM EDT - 9 months ago

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

Mar 26, 2025, 10:21 AM EDT - 9 months ago

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Mar 26, 2025, 7:30 AM EDT - 9 months ago

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Mar 4, 2025, 3:16 PM EST - 10 months ago

Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:30 AM EST - 10 months ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:30 AM EST - 10 months ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Feb 6, 2025, 8:30 AM EST - 11 months ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Jan 8, 2025, 1:35 AM EST - 1 year ago

Wave Life Sciences Is A Buy On Pipeline Prospects

Dec 23, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Dec 16, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Nov 12, 2024, 12:20 PM EST - 1 year ago

Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:45 PM EDT - 1 year ago

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Oct 16, 2024, 4:43 PM EDT - 1 year ago

Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst

Oct 16, 2024, 2:43 PM EDT - 1 year ago

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

CSCO GWW SAP WLK

Oct 16, 2024, 11:19 AM EDT - 1 year ago

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans

Oct 16, 2024, 8:25 AM EDT - 1 year ago

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Oct 1, 2024, 9:20 AM EDT - 1 year ago

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

YFZ450 Dec. 27 at 6:52 PM

$WVE half the MC of $HIMS on a phase one trial lol so whos under valued and whos over valued?? And bought and paid for analyst calling for a higher mc... scam job 101

0 · Reply

satrasal Dec. 27 at 4:45 PM

0 · Reply

History101 Dec. 26 at 6:53 PM

$WVE 5d and 1mo charts look great!!

0 · Reply

History101 Dec. 25 at 3:12 AM

$WVE lovin the 5d chart

0 · Reply

kshonstocks Dec. 24 at 4:52 PM

$WVE turning back up

0 · Reply

MansNotHot123 Dec. 24 at 3:52 PM

$WVE shorting here 18.40

0 · Reply

johnnygogogo Dec. 24 at 3:32 PM

0 · Reply

B_B_ Dec. 24 at 3:13 PM

$TMC $WVE $ORCL Green, green, green, it's already a Merry Christmas for me!

0 · Reply

VignetteVestor Dec. 24 at 11:56 AM

$WVE Current positioning will be tested as management navigates capital constraints while advancing core initiatives. Clear inflection points are required to justify renewed interest.

0 · Reply

Mantraset3 Dec. 24 at 9:42 AM

$WVE taking profit here before year end, a lot of time still needed for more approvals / stage trials — will be interesting to get back in at under $10. Merry Christmas!

1 · Reply

MansNotHot123 Dec. 23 at 5:33 PM

$WVE brrrrrr

0 · Reply

johnnygogogo Dec. 23 at 3:39 PM

$WVE did the secondary offering ever close or did stat news intentionally keep that from happening? There was never a closing announcement

1 · Reply

B_B_ Dec. 23 at 3:34 PM

$WVE $ORCL Oracle $202 tomorrow

1 · Reply

YFZ450 Dec. 23 at 3:21 PM

$WVE wait until the liver damage data comes out, trade it dont hold it as it all comes to light eventually

1 · Reply

B_B_ Dec. 23 at 3:09 PM

$WVE $ORCL time to recover

0 · Reply

B_B_ Dec. 23 at 2:45 PM

$WVE Even Novo Nordisk’s largest obesity competitor, Eli Lilly, is up today. Biotech FOMO!

0 · Reply

B_B_ Dec. 23 at 2:41 PM

$WVE $19.11

0 · Reply

B_B_ Dec. 23 at 1:57 PM

$WVE The approval of the first oral GLP-1 medicine for obesity has put the biotech sector, particularly obesity treatments, back in the spotlight. I think Novo Nordisk’s competitors are once again behind, and the urgency to catch up could bode well for WVE-007, a next-generation obesity therapy. Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S. Barron‘s • 2h ago https://www.webull.com/news/14075975625884672

0 · Reply

B_B_ Dec. 23 at 11:15 AM

$ORCL $WVE Oracle is expected to be down in the morning due to intraday profit-taking but it will close positively!

0 · Reply

B_B_ Dec. 23 at 8:56 AM

$WVE Biotech stocks that lagged during regular trading hours gained in after-hours trading, driven by Novo Nordisk and the broader “Everything Rally”. I think this could reignite FOMO in the biotech sector. NVO +0.02% +9.48% NMRA +3.43% +16.02% BRTX +0.87% + 6.90% RNXT -3.23% +4.44% IDYA +5.81% +6.49% HCTI -30.57% +6.73% ATEC +3.45% +2.80% Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers December 22, 2025 — Written by RTTNews.com (RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. … https://www.nasdaq.com/articles/biotech-stocks-shine-after-hours-novo-nordisk-ideaya-healthcare-triangle-among-gainers

0 · Reply

B_B_ Dec. 23 at 8:55 AM

$WVE WVE-007 offers fat loss benefits comparable to GLP-1 therapies, without sacrificing muscle mass or causing the gastrointestinal issues commonly associated with them. In addition, it requires no changes to diet or exercise and only one or two doses per year, rendering the method of administration largely irrelevant.

0 · Reply

B_B_ Dec. 23 at 8:55 AM

$WVE The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s Wegovy pill, a once-daily medication and the first oral GLP-1 therapy for the treatment of obesity in the United States. However, the drug can cause gastrointestinal side effects and may potentially lead to muscle loss. The pill is indicated for use in conjunction with a reduced-calorie diet and increased physical activity.

0 · Reply

Market Cap	2.97B
Revenue (ttm)	108.30M
Net Income (ttm)	-97.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.58%
Debt to Equity Ratio	0.00

Volume	2,168,100
Avg Vol	7,406,330
Day's Range	N/A - N/A
Shares Out	167.18M
Stochastic %K	78%
Beta	-1.72
Analysts	Strong Sell
Price Target	$31.60